Detail akcie AbbVie Inc online

Business Summary: AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, ELAHERE, IMGN-151, Pivekimab Sunirine and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities and more. The Company offers a PINK1 activator which is designed to address mitochondrial dysfunction.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, AbbVie Inc revenues decreased 6% to $54.32B. Net income applicable to common stockholders decreased 59% to $4.82B. Revenues reflect United States segment decrease of 7% to $39.81B, Europe segment decrease of 27% to $3.04B. Net income also reflects Research and development increase of 8% to $6.76B (expense), Advertising Expense increase of 10% to $2.2B (expense).